Enhanced Stim1 expression is associated with acquired chemo-resistance of cisplatin in osteosarcoma cells

• Published in: Human cell : official journal of Human Cell Research Society 2017-07, Vol.30 (3), p.216-225
• Main Authors: Sun, Xilong, Wei, Qiang, Cheng, Jie, Bian, Yanzhu, Tian, Congna, Hu, Yujing, Li, Huijie
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Apoptosis - genetics; Biomedical and Life Sciences; Bone cancer; Bone Neoplasms - genetics; Bone Neoplasms - metabolism; Bone Neoplasms - pathology; Calcium; Calcium - metabolism; Calcium influx; Cancer; Cell Biology; Cell Line, Tumor; Chemotherapy; Cisplatin; Cisplatin - pharmacology; Drug Resistance, Neoplasm - genetics; Endoplasmic reticulum; Endoplasmic Reticulum Stress - drug effects; Gene Expression; Gene Expression Regulation, Neoplastic - genetics; Genetic Association Studies; Gynecology; Humans; Life Sciences; Neoplasm Proteins - genetics; Neoplasm Proteins - metabolism; Neoplasm Proteins - physiology; Oncology; Osteosarcoma; Osteosarcoma - genetics; Osteosarcoma - metabolism; Osteosarcoma - pathology; Osteosarcoma cells; Reproductive Medicine; Research Article; siRNA; Stem Cells; STIM1 protein; Stromal Interaction Molecule 1 - genetics; Stromal Interaction Molecule 1 - metabolism; Stromal Interaction Molecule 1 - physiology; Surgery; Survival; Up-Regulation
• ISSN: 1749-0774; 0914-7470; 1749-0774
• DOI: 10.1007/s13577-017-0167-9

Osteosarcoma is the most common primary malignant bone tumor. Although cisplatin is the primary chemotherapy used in osteosarcoma treatment, the cisplatin resistance remains a big challenge for improving overall survival. The store-operated calcium (Ca 2+ ) entry (SOCE) and its major mediator Stim1 have been shown to be implicated in a number of pathological processes typical for cancer. In this study, we showed that Stim1 expression was significantly increased in chemo-resistant osteosarcoma tissues compared with chemo-sensitivity tissues. Patients with Sitm1 expression exhibited poorer overall survival than Stim1-negative patients. Moreover, un-regulation of Stim1 expression and SOCE were also observed in cisplatin-resistant MG63/CDDP cells compared with their parental cells. Cisplatin treatment obviously reduced Stim1 expression and SOCE in cisplatin-sensitivity MG63 cells, but had no effects on MG63/CDDP cells. In addition, cisplatin resulted in a more pronounced increase of endoplasmic reticulum (ER) stress in MG63 cells than in their resistant variants, which was evidenced by the activation of molecular markers of ER stress, GRP78, CHOP and ATF4. Knockdown of Stim1 using siRNA remarkably enhanced cisplatin-induced apoptosis and ER stress in MG63/CDDP cells, thereby sensitizing cancer cells to cisplatin. On the other hand, overexpression of Stim1 markedly reversed apoptosis and ER stress following cisplatin treatment. Taken together, these results demonstrate that Stim1 as well as Ca 2+ entry contributes cisplatin resistance via inhibition of ER stress-mediated apoptosis, and provide important clues to the mechanisms involved in cisplatin resistance for osteosarcoma treatment. Stim1 represents as a target of cisplatin and blockade of Stim1-mediated Ca 2+ entry may be a useful strategy to improve the efficacy of cisplatin to treat osteosarcoma.